EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Final Analysis Results from the AGEHA Study: Emicizumab Prophylaxis for Acquired Hemophilia A with or without Immunosuppressive Therapy

Midori Shima, Nobuaki Suzuki, Hidekazu Nishikii, Kagehiro Amano, Yoshiyuki Ogawa, Ryota Kobayashi iD, Ryoto Ozaki iD, Koichiro Yoneyama iD, Narumi Mizuno, Emiko Sakaida, Makoto Saito, Takashi Okamura und 5 weitere

Thrombosis and Haemostasis · 01.05.2025 · 125 (05) · 449-459

DOI: 10.1055/a-2384-3585 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.05.2025. Verfasst von Midori Shima und 16 weiteren Autor:innen. Beteiligte Einrichtung: Thrombosis and Hemostasis Research Center, Nara Medical University, Kashihara, Japan. Hauptthemen laut MEDLINE: Hemophilia A, Antibodies, Monoclonal, Humanized, Antibodies, Bispecific, Immunosuppressive Agents. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chugai Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary analysis of the phase III AGEHA study suggested a favorable benefit–risk profile for emicizumab prophylaxis in patients with acquired hemophilia A (PwAHA); however, only patients undergoing immunosuppressive therapy (IST; Cohort 1) were included. To present final analysis results of AGEHA, including data on IST-ineligible patients (Cohort 2) and on long-term prophylaxis with emicizumab. For patients in both Cohorts 1 and 2, emicizumab was administered subcutaneously at 6 mg/kg on Day 1, 3 mg/kg on Day 2, and 1.5 mg/kg once weekly from Day 8 onward. Twelve patients (Cohort 1) and two patients (Cohort 2) were enrolled. Duration of emicizumab treatment was 8 to 639 days (median: 44.5 days) in Cohort 1 and 64 and 450 days in Cohort 2. In both cohorts, no major bleeds were observed after initial emicizumab administration. Six patients started their first rehabilitation sessions during emicizumab treatment and no rehabilitation-related bleeds occurred. Twenty-three surgeries were performed under emicizumab prophylaxis and there were no bleeds related to surgeries. Although asymptomatic deep vein thrombosis was reported in one patient in the primary analysis, no other thrombotic events occurred thereafter. Two patients developed anti-emicizumab antibodies, one of whom showed accelerated emicizumab clearance. Tailored IST approaches (delayed initiation, no use, or reduced dose) were successfully executed in three patients undergoing emicizumab prophylaxis. These results suggest that emicizumab prophylaxis has a favorable benefit–risk profile in PwAHA regardless of eligibility for IST.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AAntibodies, Monoclonal, HumanizedAntibodies, BispecificImmunosuppressive AgentsHumansMaleMiddle AgedAdultFemaleTreatment OutcomeFactor VIIIAgedHemorrhageTime FactorsDrug Administration ScheduleYoung Adult

Substanzen

emicizumabAntibodies, Monoclonal, HumanizedAntibodies, BispecificImmunosuppressive AgentsFactor VIII

Autor:innen und Institutionen

  • Thrombosis and Hemostasis Research Center, Nara Medical University, Kashihara, Japan.
  • Department of Pediatrics, Nara Medical University, Kashihara, Japan.
  • Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan.
  • Department of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
  • Department of Laboratory Medicine, Tokyo Medical University Hospital, Tokyo, Japan.
  • Department of Hematology, Gunma University Graduate School of Medicine, Maebashi, Japan.

ORCID-Profile: Ryota Kobayashi, Ryoto Ozaki, Koichiro Yoneyama

Förderung

  • Chugai Pharmaceutical

Zitieren

APA

Shima, M., Suzuki, N., Nishikii, H., Amano, K., Ogawa, Y., Kobayashi, R., Ozaki, R., Yoneyama, K., Mizuno, N., Sakaida, E., Saito, M., Okamura, T., Ito, T., Hattori, N., Higasa, S., Seki, Y., & Nogami, K. (2025). Final Analysis Results from the AGEHA Study: Emicizumab Prophylaxis for Acquired Hemophilia A with or without Immunosuppressive Therapy. Thrombosis and Haemostasis, 125(05), 449-459. https://doi.org/10.1055/a-2384-3585

Vancouver

Shima M, Suzuki N, Nishikii H, Amano K, Ogawa Y, Kobayashi R, et al. Final Analysis Results from the AGEHA Study: Emicizumab Prophylaxis for Acquired Hemophilia A with or without Immunosuppressive Therapy. Thrombosis and Haemostasis. 2025;125(05):449-459. doi:10.1055/a-2384-3585

BibTeX
@article{Shima2025,
  author = {Shima, Midori and Suzuki, Nobuaki and Nishikii, Hidekazu and Amano, Kagehiro and Ogawa, Yoshiyuki and Kobayashi, Ryota and Ozaki, Ryoto and Yoneyama, Koichiro and Mizuno, Narumi and Sakaida, Emiko and Saito, Makoto and Okamura, Takashi and Ito, Toshihiro and Hattori, Norimichi and Higasa, Satoshi and Seki, Yoshinobu and Nogami, Keiji},
  title = {Final Analysis Results from the AGEHA Study: Emicizumab Prophylaxis for Acquired Hemophilia A with or without Immunosuppressive Therapy},
  journal = {Thrombosis and Haemostasis},
  year = {2025},
  volume = {125},
  number = {05},
  pages = {449--459},
  doi = {10.1055/a-2384-3585}
}
Kostenlos starten →